- Published at
- by seekingalpha.com
neutral
neutral
Achilles Therapeutics announces voluntary Nasdaq delisting, SEC deregistration (ACHL)
Achilles Therapeutics (ACHL) plans to delist from Nasdaq and initiate voluntary liquidation.
News for Achilles Therapeutics plc (ACHL)
- Published at
- by gurufocus.com
positivepositiveAchilles Therapeutics Announces Voluntary Nasdaq Delisting and SEC Deregistration
LONDON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc ( ACHL) (the Company) today announced that it has formally notified The Nasdaq Stock Marke- Published at
- by benzinga.com
negativenegativeAchilles Therapeutics Announces $12M AstraZeneca Deal, Plans Job Cuts - AstraZeneca (NASDAQ:AZN), Achilles Therapeutics (NASDAQ:ACHL)
Achilles Therapeutics announces a $12M deal with AstraZeneca for TRACERx data and plans job cuts following its strategic review.- Published at
- by gurufocus.com
mixedmixedAchilles Therapeutics Announces Sale of Technology Assets to AstraZeneca
- Proprietary data and samples from TRACERx and Achilles' Material Acquisition Platform (MAP) will be transferred to AstraZeneca under the Transaction - - Co- Published at
- by gurufocus.com
positivepositiveAchilles Therapeutics Receives Approval to Transfer to Nasdaq Capital Market
LONDON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc ( ACHL) today announced that on November 15, 2024, the Listing Qualifications department o- Published at
- by manilatimes.net
positivepositive- Published at
- by globenewswire.com
mixedmixed80+ Pharma Companies Unite to Shape the Future of RNA-Based Therapeutics | DelveInsight
With over 80 key companies active in the RNA therapies space, the market is projected to grow due to advancements in mRNA, siRNA, and antisense...- Published at
- by zacks.com
neutralneutralIs Achilles Therapeutics (ACHL) Stock Outpacing Its Medical Peers This Year?
Here is how Achilles Therapeutics PLC Sponsored ADR (ACHL) and Butterfly Network, Inc. (BFLY) have performed compared to their sector so far this year.- Published at
- by seekingalpha.com
mixedmixed- Published at
- by investing.com
neutralneutralAchilles Therapeutics stock hits 52-week low at $0.71 By Investing.com
Achilles Therapeutics stock hits 52-week low at $0.71- Published at
- by investorplace.com
neutralneutralACHL Stock Earnings: Achilles Therapeutics Meets EPS for Q2 2024
ACHL stock results show that Achilles Therapeutics met analyst estimates for earnings per share the second quarter of 2024.- Published at
- by seekingalpha.com
mixedmixed- Published at
- by marketscreener.com
mixedmixedAchilles Therapeutics : THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION
THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to the action to be taken, please seek your own financial advice from...- Published at
- by seekingalpha.com
mixedmixed- Published at
- by etfdailynews.com
mixedmixedStock Analysts’ Price Target Changes for May 27th (ACHL, ADEVF, ANPCY, ATDRY, ATGSY, AVDL, BKKVF, BMEA, BNDSF, BNTGY)
Read Stock Analysts’ Price Target Changes for May 27th (ACHL, ADEVF, ANPCY, ATDRY, ATGSY, AVDL, BKKVF, BMEA, BNDSF, BNTGY) at ETF Daily News- Published at
- by etfdailynews.com
positivepositiveHead-To-Head Review: Achilles Therapeutics (NASDAQ:ACHL) and Outlook Therapeutics (NASDAQ:OTLK)
Read Head-To-Head Review: Achilles Therapeutics (NASDAQ:ACHL) and Outlook Therapeutics (NASDAQ:OTLK) at ETF Daily News- Published at
- by etfdailynews.com
mixedmixedStock Analysts’ Price Target Changes for May 10th (ABC, ACB, ACHL, ACM, ADDYY, AES, AGL, AHEXY, AHT, ALB)
Read Stock Analysts’ Price Target Changes for May 10th (ABC, ACB, ACHL, ACM, ADDYY, AES, AGL, AHEXY, AHT, ALB) at ETF Daily NewsZSYELPWTRGUDRTTCFTCRXSWAVOCULMTZMRSNMKTWMAXRMAALSXM35.SALPSNKMERFKLRJUN3.DEJGHHYJGHAFINGICPTHSKAFWONKFWONBFWONADUKDTDLRCWGRPCTVACTLPCOWNLCOWNCOTYCICGNXBLDPBBVD.BAAMGNAMEALIMALBABCZFABCMABC.LWFCUAATREXTDUPSTRORYRBLXNOWLSXMKLSXMBLSXMAJPMMLJPMCL.SNJPMC.BAJPMHRTXGRPNGMREGLTFLLESTCEQRDBN.MXDBK.PRDBK.MIDBK.DEDBCSTLCSN.MXCSGNE.SWCSGN.SWCSGKFCSCOINCF.TOCCORFBYMOFBMWYYBMWM5N.MXBMW3.DEBMW.MIBMW.DEBLUEBLFSBIGBEBCY.DEBCSN.MXBCS.BABCSBCLYFBARC.LBAMXFAPDANNXACHL0QKU.L0IIB.L0I4P.LWVRRMVRNSUNMUBSN.MXUBSGEE.SWUBSGE.SWUBSG34.SAUBSG.SWUBSU1NM34.SATUERFTRVC.DETNT-UN.TOSPGSNOWSKSBFSKBSYSKAB.PRSIBNRPDROKRNGRLAYRIDERCMPRAXPLUGPLTROPYOPKNRSDYNODO.OLNOD.OLNEWRNDCVFNCMIMGAMDGLMDMCKLOTZLNCLBRDAIRTHSBC.BAHSBC-PAHSBCHSBA.LHSB.PAHIMSHCCHBIHBCYFHBCN.MXHBC1.DEH1SB34.SACRSPCRDFCPTCARGCANOC.MXC.BACBTAIAVBAHEXYAGLADDYY0LJN.L0005.HK- Published at
- by markets.businessinsider.com
mixedmixedThe Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Au...ZIVOPFED.BAPFECL.SNPFE.MXPFE.DEPFEMDNA.TOMDNAJAZZHARPFUSNCODXCAPRBNTXN.MXBNTX0A50.L0A3M.LZLDPFZIOPZGNXZEALXCURVYNEVYGR.MXVYGRVECTTXMDTRVNTRIL.TOTRILTLGTTFFPTARASPRBSONNRVMDRPIDRMTIPROGPRAXPMCBDPMCBPBLAPASGORTXNKTRNBIXMRNA.MXMRNAMNOVMBRXM1RN34.SALVTXLUMOLMNLKRONKPTIKNSAJAGXITRMIRWDIRTCINCYINABIMRAIKTI1NC34.SAHRTXHOTHHOOKHBIOGTBPGRFSGRFPN.MXGRF.MCGIS.DEGILDD.BAGILD.MXGILDGIKLYGIFOFGIFLFFMTXFLXNFGEN.MXFGENEYEGEWTXEPZMENSCWENSCDVAXDRNADMACCTMXCLRBCELUBXRXBUWA.DEBPTHBMEABIOLBIO-BBIOBDSXBAX.MXBAXAYTUAXSMATAIARDSALLOALKSALIMAKROAGLEACHLACAD4875.T0UNL.L0QK8.L0M3O.L0K6R.L0J9P.L0J4V.L0IL8.L0IDA.L0HKF.L0A8M.L0A7L.L0A4W.L0A45.LSESNJNJINVADJNJ3.BADJNJ2.BAARNAAPREABVC0S54.L- Published at
- by marketscreener.com
mixedmixedAchilles Therapeutics : THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION (Form 6-K)
THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to the action to be taken, please seek your own financial advice from... | May 26, 2021- Published at
- by tradersinsight.news
mixedmixedThe Daily Biotech Pulse: April 9, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Negative Regulatory Tidings For Provention Bio, Celcuity Soars On In-licensing Deal, 2 IPOs